A comprehensive view of Daiichi Sankyo Company Ltd.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.
J&J seeks FDA approval for Tremfya guselkumab to treat adults with moderate to severe active ulcerative colitis, UK approves Daiichi Sankyo’s oral acute myeloid leukemia drug Vanflyta; UK also approves Pfizer’s Velsipity etrasimod
Published:
March 12, 2024
by FiercePharma
|
Daiichi Sankyo to invest US$1.08B to expand its production and development site in Pfaffenhofen, Germany, to enhance its capabilities in the antibody-drug conjugate field; the project is expected to create 350 jobs by 2030
Published:
February 21, 2024
by FiercePharma
|
FDA grants priority review to AstraZeneca and Daiichi Sankyo's sBLA for Enhertu; drug could be the first HER2-directed treatment and antibody drug conjugate to treat adult patients with unresectable or metastatic HER2-positive solid tumors
Published:
February 05, 2024
by Contify Life Science News
|
Daiichi Sankyo raises sales forecast for AstraZeneca-partnered Enhertu to US$2.6B due to positive developments outside the US, despite lowering the drug's sales estimate in the US to US$1.58B
Published:
February 05, 2024
by FiercePharma
|
AstraZeneca and Daiichi Sankyo announce priority review status in the US for Enhertu, a treatment for adults with certain solid tumors without other satisfactory treatment options; product is a jointly developed antibody drug conjugate
Published:
January 29, 2024
by AstraZeneca AB
|
Ask us about our Tissue & Hygiene market view